Cargando…
The Short-term Effect of a Single Lapse in Anti–Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice
PURPOSE: Diabetic macular edema (DME) is a leading cause of vision loss in diabetics. Anti–vascular endothelial growth factor (VEGF) therapy has been shown to be an effective treatment option for DME, although the injections are costly and require frequent visits, which increases the risk for uninte...
Autores principales: | Yalamanchili, Siri P., Maatouk, Christopher M., Enwere, Daniel U., Conti, Thais F., Hom, Grant L., Briskin, Isaac N., Greenlee, Tyler E., Babiuch, Amy S., Singh, Rishi P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335491/ https://www.ncbi.nlm.nih.gov/pubmed/32640254 http://dx.doi.org/10.1016/j.ajo.2020.06.040 |
Ejemplares similares
-
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis
por: Babiuch, Amy S., et al.
Publicado: (2019) -
Prostaglandin-Induced Cystoid Macular Edema Following Routine Cataract Extraction
por: Agange, Negin, et al.
Publicado: (2010) -
Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010) -
When is macular edema not macular edema? An update on macular telangiectasia type 2
por: Wu, Lihteh
Publicado: (2015) -
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
por: Veloso, Carlos E., et al.
Publicado: (2021)